Clinical trials: sponsored by China National Center for Cardiovascular Diseases
Coronary Artery Disease, Therapeutics
PEACE Prospective Study of Patients With Three-vessel Disease
Coronary heart disease (CHD) pose a serious health threaten to population. Optimal revascularization strategy in multiple vessel coronary artery disease patients remains a subject of debate between interventional cardiologists…
- Conditions
- Coronary Artery Disease, Therapeutics, Outcome Assessment
- Trial name
- PEACE3VD (NCT01617785)
- Where
- China
- Volunteers
- 4,500 people
- Sponsor
- China National Center for Cardiovascular Diseases
Coronary Artery Disease
Comparison of One-stop Hybrid Revascularization Versus Off-pump Coronary Artery Bypass for the Treatment of Multi-vessel Disease
The "one-stop" hybrid coronary revascularization combines minimally invasive direct coronary artery bypass (MIDCAB) and PCI to be performed in the hybrid operating suite, an enhanced operating room equipped with radiographic…
- Trial name
- NCT01034371
- Testing
- Minimally invasive direct coronary artery bypass, PCI-Drug eluting stents, Off-pump coronary artery bypass
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- China National Center for Cardiovascular Diseases
Coronary Artery Disease
Comparison of One-stop Hybrid Revascularization Versus Percutaneous Coronary Intervention for the Treatment of Multi-vessel Disease
The "one-stop" hybrid coronary revascularization combines minimally invasive direct coronary artery bypass (MIDCAB) and PCI to be performed in the hybrid operating suite, an enhanced operating room equipped with radiographic…
- Trial name
- NCT01035034
- Testing
- Hybrid MIDCAB/PCI, PCI with DES
- Where
- 2 sites in China
- Volunteers
- 480 people
- Sponsor
- China National Center for Cardiovascular Diseases
Ischemic Cardiomyopathy, Congestive Heart Failure
CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy
The purpose of this study is in a phase I/II safety and efficacy study to evaluate the clinical effect of coronary artery bypass graft (CABG) combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty for…
- Conditions
- Ischemic Cardiomyopathy, Congestive Heart Failure, Coronary Artery Disease
- Trial name
- NCT00972114
- Testing
- CABG combined cardiomyoplasty, CABG combined pedicled omentum graft, CABG alone
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- China National Center for Cardiovascular Diseases
Rheumatic Valve Disease, Atrial Fibrillation
Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease
The purpose of this study is to determine whether concomitant radiofrequency Maze procedure for surgical treatment of chronic atrial fibrillation with rheumatic valve disease could provide better sinus rhythm control, improved…
- Trial name
- NCT01013688
- Testing
- Cardioblate® Surgical Ablation System
- Where
- China
- Volunteers
- 150 people
- Sponsor
- China National Center for Cardiovascular Diseases
Coronary Disease, Myocardial Infarction
Stem Cell Therapy to Improve Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting (CABG)
The purpose of this study is to determine whether intracoronary transfer of autologous bone marrow cells can induce angiogenesis, subsequently improving regional myocardial perfusion, and finally resulting in improved systolic…
- Trial name
- NCT00395811
- Testing
- Bone Marrow Stem Cell Therapy combined CABG
- Where
- China
- Volunteers
- 50 people
- Sponsor
- China National Center for Cardiovascular Diseases
Atherosclerosis
The Clopidogrel and Aspirin After Surgery for Coronary Artery Disease
Clopidogrel is a antiplatelet agent and is effective at reducing intimal hyperplasia in animal models of thrombosis.Several large clinical trials have demonstrated that clopidogrel with aspirin can reduce ischemic events and…
- Trial name
- NCT00776477
- Testing
- clopidogrel and aspirin, aspirin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- China National Center for Cardiovascular Diseases